SVP, GC
Lee Chan Henry is the Senior Vice President and General Counsel at BeOne Medicines Ltd. (NASDAQ: ONC), a global oncology company headquartered in Basel, Switzerland, focused on developing innovative, affordable cancer treatments in hematology and solid tumors.[[1]](https://www.investing.com/news/insider-trading-news/lee-chan-henry-svp-at-beone-medicines-sells-shares-worth-213568-93CH-4406833)[[2]](https://www.marketbeat.com/instant-alerts/beone-medicines-nasdaqonc-svp-chan-henry-lee-sells-664-shares-2026-01-09/)[[3]](https://www.stocktitan.net/sec-filings/ONC/form-4-be-one-medicines-ltd-insider-trading-activity-297a47dc6db6.html) In this role, Henry oversees legal affairs for the company, which was founded in 2010 by Xiao Dong Wang and John V. Oyler.[[2]](https://www.marketbeat.com/instant-alerts/beone-medicines-nasdaqonc-svp-chan-henry-lee-sells-664-shares-2026-01-09/)
Henry has recently engaged in insider trading activities, including selling 664 American Depositary Shares (ADS) on December 10-11, 2025, for $213,568 under a Rule 10b5-1 plan, and additional sales on January 7, 2026, for $220,288.[[1]](https://www.investing.com/news/insider-trading-news/lee-chan-henry-svp-at-beone-medicines-sells-shares-worth-213568-93CH-4406833)[[2]](https://www.marketbeat.com/instant-alerts/beone-medicines-nasdaqonc-svp-chan-henry-lee-sells-664-shares-2026-01-09/)[[3]](https://www.stocktitan.net/sec-filings/ONC/form-4-be-one-medicines-ltd-insider-trading-activity-297a47dc6db6.html)[[5]](https://longbridge.com/en/news/272129931) Concurrently, he exercised options to acquire shares, maintaining direct ownership of 223,106 Ordinary Shares as of early 2026, valued at approximately $75 million.[[1]](https://www.investing.com/news/insider-trading-news/lee-chan-henry-svp-at-beone-medicines-sells-shares-worth-213568-93CH-4406833)[[6]](https://www.gurufocus.com/insider/232503/chan-henry-lee) At age 57, Henry's tenure supports BeOne Medicines' robust pipeline, including FDA Priority Review for sonrotoclax and leadership in CLL treatments with Brukinsa.[[1]](https://www.investing.com/news/insider-trading-news/lee-chan-henry-svp-at-beone-medicines-sells-shares-worth-213568-93CH-4406833)[[2]](https://www.marketbeat.com/instant-alerts/beone-medicines-nasdaqonc-svp-chan-henry-lee-sells-664-shares-2026-01-09/)[[8]](https://www.morningstar.com/stocks/pinx/beigf/executive)
View full insider profile →
